This article compares diabetes diagnostics and treatment reimbursement in Poland between 2019 and 2024, highlighting the changes that occurred over these years. The review is based on an analysis of literature covering diabetes classification, diagnosis, complications, and current guidelines. Scientific articles, reviews, and relevant legislation were analyzed. Diagnostic guidelines highlight the use of glycated haemoglobin (HbA1c) and recommend genetic testing for neonatal diabetes. Reimbursements for diabetes treatment, particularly for modern devices and insulin pen needles, have improved. The 2024 guidelines highlight the importance of mental health, recommending regular psychological assessments. Guidelines have become more comprehensive, and reimbursement policies are more extensive, making access to essential therapies easier for patients. These changes aim at improving treatment outcomes and enhancing the quality of life.
